EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Days Sales Outstanding : 4.19 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Days Sales Outstanding?

EyePoint Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2023 was $0.64 Mil. EyePoint Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $14.03 Mil. Hence, EyePoint Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 4.19.

The historical rank and industry rank for EyePoint Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

EYPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.82 Med: 84.86 Max: 149.23
Current: 60.54

During the past 13 years, EyePoint Pharmaceuticals's highest Days Sales Outstanding was 149.23. The lowest was 7.82. And the median was 84.86.

EYPT's Days Sales Outstanding is ranked better than
59.35% of 888 companies
in the Biotechnology industry
Industry Median: 72.105 vs EYPT: 60.54

EyePoint Pharmaceuticals's Days Sales Outstanding declined from Dec. 2022 (157.58) to Dec. 2023 (4.19).

EyePoint Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for EyePoint Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Days Sales Outstanding Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

105.04

110.34

137.38

149.23

64.67

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															157.58	153.95	107.10	34.32	4.19

Competitive Comparison of EyePoint Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Days Sales Outstanding falls into.

EyePoint Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

EyePoint Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (15.503	+	0.805)	/	2 )	/	46.018	*	365
=	8.154					/	46.018	*	365
=	64.67

EyePoint Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.483	+	0.805)	/	2 )	/	14.028	*	365 / 4
=	0.644					/	14.028	*	365 / 4
=	4.19

EyePoint Pharmaceuticals (NAS:EYPT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

EyePoint Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Executives

Ye Liu	director	ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Dario A. Paggiarino	officer: Chief Medical Officer	4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Michael Craig Pine	officer: Chief Corp Dev.&Strat. Officer	C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Nancy Lurker	director, officer: President and CEO	PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p.	10 percent owner	21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Anthony P Adamis	director	3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension	10 percent owner	56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston	officer: Chief Financial Officer	124 CHATHAM STREET, CHATHAM NJ 07928
Wendy F Dicicco	director
David Scott Jones	officer: SVP & Chief Commercial Officer	C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
John B. Landis	director	1700 KENT AVENUE, WEST LAFAYETTE IN 46906
Jay S. Duker	director	C/O ELEVEN BIOTHERAPEUTICS, 215 1ST ST. #400, CAMBRIDGE MA 02142
Douglas Evan Godshall	director	SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000